PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
| Autor: | Melanie Danzl, Bettina G. Zelger, Susanne Sprung, Andreas Pircher, Josef Fritz, Isabel Heidegger, Andrea Brunner, Renate Pichler |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology PD-L1 medicine.medical_specialty medicine.medical_treatment survival Metastasis Cystectomy 03 medical and health sciences 0302 clinical medicine cystectomy Internal medicine Biopsy Medicine Chemotherapy Hematology Bladder cancer medicine.diagnostic_test business.industry Immunotherapy medicine.disease Surgery 030104 developmental biology 030220 oncology & carcinogenesis Biomarker (medicine) bladder cancer immunotherapy business Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Renate Pichler 1, * , Isabel Heidegger 1, * , Josef Fritz 2 , Melanie Danzl 3 , Susanne Sprung 3 , Bettina Zelger 3 , Andrea Brunner 3 and Andreas Pircher 4 1 Department of Urology, Medical University Innsbruck, Innsbruck, Austria 2 Department of Medical Statistics, Informatics and Health Economics, Medical University Innsbruck, Innsbruck, Austria 3 Department of Pathology, Division of General Pathology, Medical University Innsbruck, Innsbruck, Austria 4 Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria * These authors have contributed equally to this work Correspondence to: Renate Pichler, email: Renate.Pichler@i-med.ac.at Keywords: bladder cancer, cystectomy, survival, PD-L1, immunotherapy Received: May 10, 2017 Accepted: June 30, 2017 Published: August 03, 2017 ABSTRACT Platinum-based chemotherapy is the standard of care in metastatic bladder cancer. With the approval of various checkpoint inhibitors, immunotherapy has revolutionized the traditional treatment modalities. The aim of the study was to evaluate whether PD-L1 expression on tumor cells (TCs) and tumor-infiltrating immune cells (ICs) can be used as biomarker to predict recurrence-free survival (RFS), overall survival (OS) and disease-specific survival (DSS) in bladder cancer patients after radical cystectomy (RC) developing disease recurrence followed by first-line chemotherapy. PD-L1 was measured on formalin-fixed, paraffin-embedded tissue sections of RC specimens in all patients (n=61) and in 27 matched metastatic biopsy samples by immunohistochemistry. PD-L1 expression on TCs was defined by the percentage of PD-L1 positive tumor cells (< 1%= IC0, ≥1% but |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|